teclistamab,daratumumab,talquetamab
janssen,genmab
['majestec-1', 'trimm-2', 'oreo', 'janssenus', 'janssen']
 2022 updates:
at #asco 2022, presented updated efficacy and safety data from the ongoing phase i/ii majestec-1 trial. moreover, the company also presented the results of the phase i trimm-2 study. get more details, at: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry